Thyrotropin-releasing hormone: role in the treatment of West syndrome and related epileptic encephalopathies.

Abstract

Thyrotropin-releasing hormone (TRH) has been successfully used for treating children with neurologic disorders including epilepsy. The effectiveness of TRH and a TRH analog has been reported in West syndrome, Lennox-Gastaut syndrome, and early infantile epileptic encephalopathy that were intractable to anticonvulsants and adrenocorticotrophic hormone (ACTH). However, the peptide has not been widely studied as a treatment of intractable epilepsy outside Japan. TRH is safe in children and effective in some cases of West syndrome and Lennox-Gastaut syndrome. TRH is considered as a possible new strategy for treating West syndrome and Lennox-Gastaut syndrome prior to ACTH therapy, especially for the patient with an infection, immunosuppression, or severe organic lesions in the brain. The mechanisms of its antiepileptic action may differ from those of other antiepileptic drugs. One possibility is that TRH may act as an antiepileptic through a kynurenine mechanism, considering that kynurenic acid acts as an antagonist on the N-methyl-D-aspartate receptor complex.

• Authors: Y Takeuchi, T Takano, J Abe, S Takikita, M Ohno
• Journal: Brain & development (Brain Dev) Vol. 23 Issue 7 Pg. 662-7 (Nov 2001) ISSN: 0387-7604 [Print] Netherlands
• PMID: 11701274 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Kynurenine
• Thyrotropin-Releasing Hormone

Topics

• Child
• Epilepsy (drug therapy, physiopathology)
• Humans
• Infant
• Kynurenine (physiology)
• Spasms, Infantile (drug therapy, physiopathology)
• Thyrotropin-Releasing Hormone (therapeutic use)